Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,614 across all filing types
Latest filing 2026-05-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于股票交易异常波动的公告
Regulatory Filings Classification · 92% confidence The document is an official announcement by Shenzhen Haier Bio Engineering Co. regarding abnormal fluctuations in its stock trading over consecutive days, providing explanations and risk warnings as required by the Shenzhen Stock Exchange. It does not contain financial statements, meeting materials, voting results, or any specific form filings (e.g., 10-K, IR). It serves as a regulatory disclosure notice under exchange rules, fitting the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-26 Chinese
第十届董事局第九次会议决议公告
Board/Management Information Classification · 85% confidence The document is an official announcement of the board of directors’ meeting resolutions (第十届董事局第九次会议决议公告), detailing the convening of the board meeting, proposals considered, and voting results. This falls under Board/Management Information.
2026-05-22 Chinese
关于股票交易严重异常波动暨风险提示公告
Regulatory Filings Classification · 88% confidence The document is an official announcement under Shenzhen Stock Exchange rules regarding severe abnormal stock price fluctuations and associated risk warnings. It does not present financial statements, voting results, dividends, or detailed audit data, nor is it a capital or M&A update. It is a general regulatory disclosure, making it a Regulatory Filing (RNS).
2026-05-20 Chinese
关于为控股子公司提供担保实施情况的公告
Regulatory Filings Classification · 80% confidence The document is a corporate announcement (“公告”) by Shenzhen Haiwang Bioengineering Co., Ltd. detailing guarantees provided by the parent company for its subsidiaries’ bank credit facilities. It does not contain financial statements or substantive periodical results, nor is it a meeting presentation, proxy statement, or management report. Rather, it is a general regulatory disclosure of contingent liabilities (guarantees), which does not neatly fit into any more specific category. Therefore, under the fallback classification, it is a Regulatory Filing (RNS).
2026-05-20 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 90% confidence The document is a stock exchange regulatory disclosure titled “关于股票交易异常波动的公告” detailing the company’s investigation of abnormal share price movements and compliance with Shenzhen Stock Exchange rules. It contains no financial statements, call transcripts, board changes, or dividend details, nor is it announcing or soliciting votes. It is a general regulatory announcement, fitting the fallback category Regulatory Filings (RNS).
2026-05-17 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations of Shenzhen Haiwang Bioengineering Co., Ltd. It explains the situation, confirms no undisclosed material information, and provides a risk warning. It references a previously disclosed audit report with a qualified opinion but does not contain the audit report itself or detailed financial data. The document is short (1049 characters) and serves as a regulatory disclosure about stock price movements and compliance with disclosure rules. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other specific categories like Audit Report or Earnings Release.
2026-05-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.